Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GI Innovation, Inc.
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Mayo Clinic
Neonc Technologies, Inc.
Bristol-Myers Squibb
Genmab
Pfizer
Merck Sharp & Dohme LLC
University of California, Davis
Hoffmann-La Roche
Ocellaris Pharma, Inc.
Tyra Biosciences, Inc
Memorial Sloan Kettering Cancer Center
Alentis Therapeutics AG
H. Lee Moffitt Cancer Center and Research Institute
Tanabe Pharma America, Inc.
BeOne Medicines
M.D. Anderson Cancer Center
Astellas Pharma Inc
Dana-Farber Cancer Institute
ITM Oncologics GmbH
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Incyte Corporation
National Institutes of Health Clinical Center (CC)
NuCana plc
National Cancer Institute (NCI)
Inovio Pharmaceuticals
Klus Pharma Inc.
Aprea Therapeutics
Hoosier Cancer Research Network
The Netherlands Cancer Institute
ImmunityBio, Inc.
PureTech
Hoosier Cancer Research Network
RAPT Therapeutics, Inc.
Cybrexa Therapeutics
Salubris Biotherapeutics Inc
AstraZeneca
Altor BioScience
Sumitomo Pharma America, Inc.
NextCure, Inc.
Evopoint Biosciences Inc.
Basilea Pharmaceutica
NanOlogy, LLC
Fred Hutchinson Cancer Center
Beijing InnoCare Pharma Tech Co., Ltd.
Nektar Therapeutics